201 related articles for article (PubMed ID: 31873038)
1. Optical quality assessment in branch retinal vein occlusion after monthly intravitreal ranibizumab injection: a prospective, case-control study.
Li L; Hu X; Yang Z; Chen X; Guo L; Zhu C; Zhang Z; Pan Q
Curr Eye Res; 2020 Aug; 45(8):1005-1011. PubMed ID: 31873038
[TBL] [Abstract][Full Text] [Related]
2. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
[TBL] [Abstract][Full Text] [Related]
3. Collateral Vessel Development in Central and Branch Retinal Vein Occlusions Are Associated With Worse Visual and Anatomic Outcomes.
Arrigo A; Aragona E; Lattanzio R; Scalia G; Bandello F; Parodi MB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):1. PubMed ID: 34724540
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
6. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.
Nishimura T; Machida S; Tada A; Oshida E; Muto T
Doc Ophthalmol; 2019 Aug; 139(1):67-74. PubMed ID: 30980231
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
11. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Noma H; Yasuda K; Shimura M
Eur J Ophthalmol; 2021 Jan; 31(1):204-210. PubMed ID: 31690095
[TBL] [Abstract][Full Text] [Related]
12. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
13. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
[TBL] [Abstract][Full Text] [Related]
14. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
Nishimura T; Machida S; Tada A; Oshida E; Muto T
Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
[TBL] [Abstract][Full Text] [Related]
15. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Optical Coherence Tomography Angiography Features and Visual Function in Eyes With Branch Retinal Vein Occlusion.
Samara WA; Shahlaee A; Sridhar J; Khan MA; Ho AC; Hsu J
Am J Ophthalmol; 2016 Jun; 166():76-83. PubMed ID: 27038893
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice.
Brynskov T; Kemp H; Sørensen TL
Retina; 2014 Aug; 34(8):1637-43. PubMed ID: 24646663
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
